Are you a Health Professional? Jump over to the doctors only platform. Click Here

Drug Combination Halts Tumor Growth Better Than Single Agent

Print Friendly, PDF & Email

Treatment with three drugs that inhibit the human epidermal growth factor receptor (HER) stops HER2-positive breast cancer tumor growth in mice better than treatment with just one or two of the drugs.

Grazia Arpino, M.D., Ph.D., of Baylor College of Medicine in Houston, and colleagues measured tumor growth in mice with human breast cancer tumors that overexpress HER2. Some mice received one of three HER inhibitors – pertuzumab, trastuzumab, or gefitinib – or a combination of two or three of the drugs. The mice also received different combinations of hormonal therapy, including estrogen supplements, estrogen withdrawl, and tamoxifen.A combination of all three HER inhibitors was more effective at slowing tumor growth than a single drug or combination of two drugs. The tumors grew after 49 days in mice that received all three drugs, compared with 21 days for mice in the estrogen-only group and 28 days for mice that got estrogen and pertuzumab. The addition of tamoxifen to any of the three drugs also inhibited tumors growth in the mice, but after two months the tumors grew resistant to the treatment. In mice treated with all three HER inhibitors plus tamoxifen or estrogen withdrawal, most tumors completely disappeared and did not progress for more than 189 days after treatment.”These results support the hypothesis that acquired resistance to the individual agents is the result of [an] incomplete blockade of this complex network at the receptor level and not activation of a different survival pathway,” the authors write.(Source: The Journal of the National Cancer Institute : Baylor College of Medicine : May 2007.)


Print Friendly, PDF & Email

Dates

Posted On: 2 June, 2007
Modified On: 16 January, 2014

Tags



Created by: myVMC